Regulation

Are peptides
legal?

It depends on where you are, how the product is presented, and who it is sold to. Here is the 2026 picture in three markets, with a full page for each.

Short answerRegulation · 6 min read · Updated 17 Nov 2026

Peptides sold as “research peptides” are not approved medicines in the US, UK or Australia, and marketing them for use in people without authorisation is unlawful in all three. A “research use only” label does not change that. Since October 2026 HHS has said it will not act against licensed compounding of six of them on prescription; Australia makes BPC-157 and TB-500 prescription-only.

Key takeaways

  • In the US, UK and Australia, regulators decide what a peptide is by how it is presented and sold, not by its label alone.
  • US: since 28 October 2026, HHS says it will not act against licensed pharmacies and physicians compounding six peptides under ten conditions; it is not an approval.
  • UK: a peptide presented or used as a medicine needs authorisation, and the MHRA has said it disregards “research purposes” claims used to avoid that.
  • Australia: the TGA says supplying unapproved peptides is unlawful; BPC-157 and TB-500 are Schedule 4 and illegal to possess without authority.
  • Sport: BPC-157 and TB-500 are prohibited at all times under the WADA List.

01The one idea that decides it

In all three markets, the law looks at what a product is for, not only at what it is called.

United States. FDA judges a product’s intended use from objective evidence: labelling, advertising, statements and the circumstances of the sale. A peptide intended for use in people without FDA approval is an unapproved new drug.

United Kingdom. A product is a medicinal product if it is presented as treating or preventing disease, or used to modify a physiological function by a pharmacological action. An unauthorised medicinal product may not be sold or supplied.

Australia. Peptide products supplied for therapeutic use are regulated as therapeutic goods. Those not on the Australian Register of Therapeutic Goods are unapproved, and the TGA says supplying them is unlawful.

02Market by market

One table, three markets. Each row links to a full page with the primary documents.

MarketA “research use only” labelSold for use in peopleWhat regulators did in 2026Full page
United StatesFDA’s 2026 warning letters said such labels did not outweigh website evidence of human use.Unapproved new drug, unless FDA-approved or lawfully compounded.HHS (28 Oct): no enforcement against licensed compounding of six peptides under ten conditions. FDA warning letters to RUO sellers.US
United KingdomThe MHRA has said it disregards “research purposes” claims used to avoid medicines rules (reported, Mar 2026).Unauthorised medicinal product under the Human Medicines Regulations 2012.MHRA said it disregards “research purposes” claims used to avoid medicines rules (Mar).UK
AustraliaThe TGA says such disclaimers do not make supply lawful or permit importation.Unlawful to import, advertise, manufacture or supply unapproved peptides. BPC-157 and TB-500 are Schedule 4.Safety advisory on research-use claims (Apr); seizures and a public statement that supplying unapproved peptides is unlawful (Aug).Australia
European Union (context)Not tracked on this site.Medicinal product needing authorisation (Directive 2001/83/EC, Art. 1).Not tracked market by market on this site.—

For BPC-157 specifically, with a dated timeline across all three markets, see is BPC-157 legal?

03Sport is a separate rulebook

Anti-doping rules apply to athletes whatever national law says. WADA’s Prohibited List names BPC-157 in class S0, non-approved substances, which covers any pharmacological substance with “no current approval by any governmental regulatory health authority for human therapeutic use”. It lists thymosin-β4 and its derivatives, such as TB-500, under S2.3. Both are prohibited at all times, and a national compounding policy does not change that. Detail: peptides and anti-doping.

04Where to go next

Market pages: United States · United Kingdom · Australia.

By topic: is BPC-157 legal? · research use only · the 2026 FDA advisory vote · the HHS policy.

What changed, when: the regulatory changelog records dated regulatory events, newest first.

Laws change, and this page is dated for that reason. What we don’t know: whether FDA will list any peptide through rulemaking, how long the US enforcement policy will last, and how state and territory rules in the US and Australia will apply to specific cases.

This is a plain-English summary of public documents, checked on 17 Nov 2026. It is not legal advice.

RefSources

  1. HHS. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (policy text and Appendix A). Policy document, Oct 2026. www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement…
  2. FDA CDER. Warning letter to Peak Performance Peptides, MARCS-CMS 735127. Warning letter, 24 Aug 2026 (posted 1 Sep 2026). www.fda.gov/inspections-compliance-enforcement-and-criminal-…
  3. The Human Medicines Regulations 2012 (SI 2012/1916), regulation 2: medicinal products. UK legislation, revised text. www.legislation.gov.uk/uksi/2012/1916/regulation/2
  4. Flett A. The peptide boom: legal ‘loophole’ fuels rise of unregulated injectables (MHRA statement, Lynda Scammell). STV News, 19 Mar 2026. Press report of an MHRA statement. news.stv.tv/scotland/the-peptide-boom-call-for-review-of-leg…
  5. TGA. Understanding your responsibilities when importing, compounding and supplying unapproved peptide products. Safety advisory, 13 Apr 2026. www.tga.gov.au/safety/safety-monitoring-and-information/safe…
  6. TGA. TGA flexes its muscle against illegal peptides and steroids. Media release, 17 Aug 2026. www.tga.gov.au/news/media-releases/tga-flexes-its-muscle-aga…
  7. Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026 (F2026L01327), Schedule 4 and Appendix D. Federal Register of Legislation, registered 30 Sep 2026. www.legislation.gov.au/F2026L01327/latest/text
  8. European Union. Directive 2001/83/EC on the Community code relating to medicinal products for human use, Article 1. Consolidated text. eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:02001L0083…
  9. World Anti-Doping Agency. The Prohibited List: S0 Non-approved substances and S2.3 Growth factors. Current List, checked 17 Nov 2026. www.wada-ama.org/en/prohibited-list

Plain-English summary of public sources, not legal or medical advice. Last checked 17 Nov 2026.

Questions

Are peptides legal in the US?

Approved peptide medicines are, on prescription. Research peptides marketed for people are unapproved new drugs; since October 2026, HHS has tolerated licensed compounding of six of them under ten conditions.

Are peptides legal in the UK?

A peptide presented or used as a medicine needs authorisation under the Human Medicines Regulations 2012. The MHRA has said it disregards “research purposes” claims used to avoid that.

Are peptides legal in Australia?

The TGA says it is unlawful to import, advertise, manufacture or supply unapproved peptide products. BPC-157 and TB-500 are Schedule 4, and possessing them without authority is illegal.

Does a “research use only” label make a product legal?

No. Regulators in all three markets look at how a product is presented and sold.

Is this legal advice?

No. It is a plain-English summary of public documents, checked on 17 Nov 2026. Laws change; ask a lawyer qualified where you are.

Evidence before hype.

One email a week: new research explained and regulatory changes. No prices, no hype.

Get the 6:00 brief

Free. Unsubscribe any time.

Written by 6AM Research. Drafted from primary sources; every claim links to its source, and the page is dated. Editorial policy · How we check every page